Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma - Related Studies - ClinicalTrials.gov

Skip to Main Content

ClinicalTrials.gov

Home Search Study Topics Glossary


	Full Text View


	Tabular View


	No Study Results Posted


	Related Studies

Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma

This study is ongoing, but not recruiting participants.

Study NCT00004066 Information provided by National Cancer Institute (NCI)

First Received: December 10, 1999 Last Updated: February 6, 2009 History of Changes

Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:

Conditions listed in this trial

Ovarian Cancer
Sarcoma
Small Intestine Cancer

Additional conditions recognized in this trial

Duodenal Neoplasms
Ileal Neoplasms
Intestinal Neoplasms
Jejunal Neoplasms
Leiomyosarcoma
Ovarian Neoplasms

Interventions listed in this trial

filgrastim
docetaxel
gemcitabine hydrochloride

Additional drug interventions recognized in this trial

Gemcitabine

More general drug interventions related to this trial

Anti-Infective Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antiviral Agents
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Radiation-Sensitizing Agents
Therapeutic Uses

Sponsors listed in this trial

Memorial Sloan-Kettering Cancer Center
National Cancer Institute (NCI)

Back to top of Main Content